Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
Hosted on MSN1d
Novo Nordisk Stock Jumps On Q4 Beat: Retail Brushes Off Slower Growth Outlook To Chase Obesity Drug BoomNYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback